Cargando…
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder characterized by excessive secretion of cytokines. Even with the recommended HLH-94/2004 regimen, over 30% of patients remain refractory to frontline therapy or relapse after an initial response, leading to poor clinical outco...
Autores principales: | Song, Yue, Li, Xiaoli, He, Xuefeng, Zhou, Fei, Du, Feng, Wang, Ziyan, Chen, Suning, Wu, Depei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339381/ https://www.ncbi.nlm.nih.gov/pubmed/37457729 http://dx.doi.org/10.3389/fimmu.2023.1211655 |
Ejemplares similares
-
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021) -
Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS
por: Liu, Xiang, et al.
Publicado: (2022) -
Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3
por: Niizato, Daiki, et al.
Publicado: (2022) -
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
por: Chi, Ying, et al.
Publicado: (2021) -
Approaching hemophagocytic lymphohistiocytosis
por: Chinnici, Aurora, et al.
Publicado: (2023)